Previous close | 2.5900 |
Open | 2.6700 |
Bid | 2.5800 x 100 |
Ask | 2.6000 x 100 |
Day's range | 2.5800 - 2.6800 |
52-week range | 1.5700 - 3.1600 |
Volume | |
Avg. volume | 2,555,064 |
Market cap | 967.606M |
Beta (5Y monthly) | 1.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5th & 6th 2024. President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Wednesday June 5th at 2:30 p.m. ETScotiabank Healthcare 1x1 Day on June 20th 2024. Management will participate in 1x1 in
SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20, 2024, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan). The equity award consisted of an award of 207,832 restricted stock units (RSUs) as a material inducement to a new empl
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, res